A manualised Post-Traumatic growth intervention for people with hematological cancers in greece
NCT ID NCT07814170
First seen Sep 10, 2026 · Last updated Sep 10, 2026
Summary
This clinical trial aims to determine whether a manualised group intervention for people with blood cancers can help them experience positive psychological changes following their diagnosis, known as post-traumatic growth. Participants receiving the intervention will be compared with those receiving usual care and placed on a waiting list. Participants will be randomly allocated to either the group intervention or the usual care/waiting-list group. The study will also explore how this intervention could be implemented within the Greek healthcare system. The study aims to answer the following main questions: (1) Does this psychological group intervention increase post-traumatic growth in people with blood cancers? (2) Does this intervention improve other outcomes, including anxiety, depression, quality of life, psychological well-being, cognitive functioning, distress, illness understanding and routine blood markers? Participants will: (1) Attend nine weekly face-to-face group sessions in Greek, each lasting approximately two hours, with other people living with blood cancers. (2) Receive a detailed manual/workbook covering the session content and be encouraged to use it between sessions. (3) Have the opportunity to participate in an optional outdoor activity of their choice. (4) Complete questionnaires and a brief cognitive assessment before and after the intervention, together with other assessments as required. Participation is voluntary and free of charge. Some participants may experience mild emotional discomfort when discussing their experiences; however, psychological support will be available if needed. The findings will help researchers determine whether this group intervention can support people living with blood cancers and inform the future implementation of similar interventions within the Greek healthcare system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2024
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Having a diagnosis of a hematological cancer * Having completed the planned hospital admission and related treatments * Having no more than 5 years since the initial diagnosis Exclusion Criteria: * Being in active psychological or psychiatric treatment * Having an unmanaged mental health difficulty * Having a severe cognitive impairment * Being unable to give informed consent * Being unable to read or speak Greek * Having one or more cancer relapses * Diagnosed with another type of cancer within 5 years prior to recruitment * Having a life expectancy of less than one year
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute lymphoid leukemia (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
General Hospital of Thessaloniki G. Papanikolaou
Thessaloniki, 54639, Greece
-
University General Hospital of Thessaloniki - AHEPA
Thessaloniki, 54636, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- ABBA CORD: double umbilical cord blood transplants with abatacept for graft versus host disease prophylaxis
- Phase 2 study of the combination of ibrutinib plus venetoclax in subjects with treatment-naïve chronic lymphocytic Leukemia/Small lymphocytic lymphoma
- Development and pilot implementation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: the SHIELD (Smart health integration for early life-saving detection)
- A phase i, Single-Arm, Open-Label clinical study to evaluate the safety, pharmacokinetics, and preliminary efficacy of CHT101 injection in subjects with Relapsed/Refractory T-Cell and B-Cell hematological malignancies
- A phase i, Single-Arm, Open-Label study to evaluate the safety, pharmacokinetics and preliminary efficacy of CHT101 injection in subjects with Relapsed/Refractory T-Cell and B-Cell hematological malignancies
- A nationwide effort to map a rare blood Cancer's toll